DURHAM – A Durham-based pharmaceutical contract development and manufacturing organization, Alcami, will invest $10 million in an expansion of its laboratory operation in the Bull City, and plans to hire 40 additional “scientific professionals,” the company noted in a statement this week.
“This investment further reinforces our commitment to our clients, allowing us to support the increasing demand for the analysis and characterization of biological molecules manufactured in our new Research Triangle Park fill-finish facility and for clients seeking stand-alone analytical support,” said Dr. Elliott Franco, Vice President of Laboratory Operations at Alcami, in a statement.
The additional investment will increase the company’s existing laboratory footprint by more than 6,700 square feet. In addition, the firm will add equipment that will enable it to “enhance drug substance and drug product characterization capabilities for biologics in all phases of development,” the statement notes.
The company will also extend its capacity to “support parenteral manufacturing projects and stand-alone analytical clients.”
In 2020, the company acquired and combined with TriPharm, including absorbing the Durham facility. As a part of that deal, the majority owner of Alcami, Madison Dearborn Partners, put more funding into the venture, WRAL TechWire reported.
The expansion of the facility is expected to double the company’s footprint, the statement noted.
Durham drug firm Alcami acquires recently launched TriPharm, new plant
